2-Oxo-PCE is a chemical compound that belongs to the arylcyclohexylamine class of substances, often referred to as dissociative anesthetics. Its full name is 2-(2-Oxo-phenyl)cyclohexanamine, and it is structurally similar to phencyclidine (PCP) and ketamine, which are well-known dissociative anesthetics.
Key Characteristics of 2-Oxo-PCE:
- Dissociative Effects: Like other substances in this category, it is believed to induce dissociation, which is a feeling of detachment from reality or oneself.
- Chemical Structure: It shares a cyclohexanone group in its molecular structure, making it chemically similar to compounds like ketamine.
- Research Chemical: 2-Oxo-PCE is not approved for medical or therapeutic use and is commonly sold as a research chemical. Its use is typically restricted to laboratory or scientific studies.
- Psychoactive Potential: Anecdotal reports suggest that it has psychoactive effects, including alterations in sensory perception, mood, and consciousness, but such reports are primarily from unsanctioned use.
- Legal Status: The legal status of 2-Oxo-PCE varies by country. In some places, it is considered a controlled substance, while in others, it is unregulated but sold under restrictions due to its potential for misuse.
Risks and Concerns:
- Limited Research: There is very little scientific literature available about its pharmacology, safety profile, or long-term effects.
- Potential for Abuse: Like other dissociative substances, it may have a potential for abuse and could pose risks of psychological dependence.
- Unknown Toxicity: The effects and safety of 2-Oxo-PCE have not been thoroughly studied, making it potentially dangerous, especially when used recreationally.
Disclaimer:
If you’re seeking information about 2-Oxo-PCE for scientific or medical purposes, ensure you consult verified sources and adhere to local laws and regulations regarding controlled substances. Recreational use or unsupervised experimentation with such chemicals can be extremely hazardous.
Reviews
There are no reviews yet.